XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
AUSTIN, Texas, March 26, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced the incorporation of its wholly owned Japanese subsidiary, XBiotech Japan KK. The creation of the Japanese Company is reportedly the first step in XBiotech's strategy to expand its clinical operations and ultimately product reach into the unique Japanese market place.
"XBiotech is committed to availing its drug development technologies to serve unmet medical need in Japan," said Erika Geimonen, Vice President of Business Development, XBiotech. "This is a very special market place and we look forward to working with the PMDA and our Japanese partners to help patients access important therapies. Whether we are talking about our True Human™ antibody therapies, or biosimilars, we offer the possibility of breakthrough with respect to how biological drugs can be used to help sustain Japanese patients and the Japanese healthcare system alike."
XBiotech's production technology is enabling unprecedented cost efficiencies. Making proprietary True Human™ biologics affordable will help enable access to new and larger markets, and promises to set a new bar for drug pricing. Yet, dramatic cost reductions for biosimilar drugs could be game changing—and permit very aggressive competition for market share for existing world-leading biological drug products. Hence, XBiotech has recently expanded its pipeline with the development of biosimilars.
The Company has developed simple, minimal infrastructure production technology, dramatically reducing capital requirements and lead times, while greatly improving regulatory compliance and production flexibility. These processes are now a cornerstone of XBiotech's commercialization platform. The Company is now equipped with know how and technology to produce the most affordable biological drug products in the world—and to establish a new paradigm for cost efficiency in the biopharmaceutical industry.
At the heart of XBiotech is its pipeline of True Human™ monoclonal antibodies, the first of a new class of better, safer therapeutic antibodies. The use of the Company's lead True Human™ antibody in clinical programs to treat acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease have created anticipation for a single therapeutic agent capable of treating multiple diseases by blocking chronic inflammation. XBiotech believes that this extraordinary lead product represents what is perhaps the greatest single-product value potential in the history of therapeutic antibodies.
XBiotech is building on a foundation of groundbreaking therapies, innovation and a commitment to unmet medical needs worldwide.